Search

Displaying results 6421 - 6430 of 8696 in total
  1. Drug

    Daphnetin

    go.drugbank.com/drugs/DB18965
    Investigational

    Daphnetin is under investigation in clinical trial NCT06329167 (Daphnetin Capsules for Lower Limb Lymphoedema Following Gynaecological Surgery).

  2. Drug

    Radavirsen

    go.drugbank.com/drugs/DB15332
    Investigational

    Radavirsen is under investigation in clinical trial NCT01375985 (Safety Study of Single Administration Intravenous Treatment for Influenza).

  3. Drug

    Norleucine

    go.drugbank.com/drugs/DB15458
    Investigational

    Norleucine is under investigation in clinical trial NCT00081952 (Amino Acid Therapy for Hot Flashes in Postmenopausal Women).

  4. Drug

    PS386113

    go.drugbank.com/drugs/DB05211
    Experimental

    PS386113 is a small molecule drug candidate under investigation for the treatment of inflammatory disorders. It is being developed by Schering-Plough and Pharmacopeia.

  5. Drug

    INS 316

    go.drugbank.com/drugs/DB05390
    Experimental

    It is selective P2y2 receptor antagonists claimed to be useful as anti-inflammatory agents.

  6. Drug

    IR501

    go.drugbank.com/drugs/DB06464
    Experimental

    IR501 (Ravax) is a potential first-in-class vaccine for the treatment of Rheumatoid Arthritis. It specifically targets autoreactive T-cells, reducing their activity.

  7. Drug

    Rebastinib

    go.drugbank.com/drugs/DB13005
    Investigational

    It is an inhibitor of Tie2 tyrosine kinase receptor and an antineoplastic agent.

  8. Drug

    ARCoV

    go.drugbank.com/drugs/DB15855
    Experimental

    As of July 2020, the vaccine candidate is set for Phase 1 clinical trials to investigate for safety, tolerance, and immunogenicity (ChiCTR2000034112). … Manufactured as a liquid, ARCoV is thermostable at room temperature for at least 1 week.

  9. Drug

    Influenza B virus B/Austria/1359417/2021 live (attenuated) antigen

    go.drugbank.com/drugs/DB16902
    Approved

    Upon re-exposure to an influenza virus, the immune system is prepared with circulating antibodies that identify and destroy the virus. … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen

  10. Drug

    Influenza A virus A/Darwin/6/2021 IVR-227 (H3N2) antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB16903
    ApprovedWithdrawn

    Upon re-exposure to an influenza virus, the immune system is prepared with circulating antibodies that identify and destroy the virus. … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen